GuidelineAmerican journal of respiratory and critical care medicine2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
Guideline in American journal of respiratory and critical care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data.The Lancet. Microbe · 2025Pooled it
- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.The Journal of antimicrobial chemotherapy · 2024Trial
- Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2018Trial
- Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.EBioMedicine · 2017Trial
- Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.Journal of clinical microbiology · 2016Trial
- Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2014Trial
- Diagnostic accuracy of the ESAT6-CFP10 skin test for latent tuberculosis infection among jail detainees.Microbiology spectrum · 2025Article
- Discovery of Novel Transketolase Epitopes and the Development of IgG-Based Tuberculosis Serodiagnostics.Microbiology spectrum · 2023Article
- Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency.Antimicrobial agents and chemotherapy · 2023Article
- Inflammatory immune profiles associated with disease severity in pulmonary tuberculosis patients with moderate to severe clinical TB or anemia.Frontiers in immunology · 2023Article
- Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden.Microbiology spectrum · 2021Article
- Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.Nature communications · 2021Article
- High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.Contemporary clinical trials · 2020Article
- Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.PLoS medicine · 2019Review
- Observational
- The serum concentration of vitamin BInternational journal of general medicine · 2019Article
- Novel T7 Phage Display Library Detects Classifiers for Active Mycobacterium Tuberculosis Infection.Viruses · 2018Article
- Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis?Frontiers in microbiology · 2018Review
- Biomarkers for Treatment Monitoring in Tuberculosis: A New Hope.EBioMedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 15 institutions in 2 countries.
Funding
Abstract
The Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. The goals were to assess recent surrogate marker research and to provide specific recommendations for (1) the qualification and validation of biomarkers of treatment outcome; (2) the standardization of specimen and data collection for future clinical trials, including a minimum set of samples and collection time points; and (3) the creation ofa specimen repository to support biomarker testing. This article summarizes these recommendations and provides a roadmap for their implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.